supp.ai
Discover Supplement-Drug Interactions
Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago
drug:
Cyproheptadine
supplement:
Vadimezan
Research Papers that Mention the Interaction
“Both diclofenac and cyproheptadine at 500 µM caused a significant inhibition of DMXAA metabolism in rat liver microsomes.”
“Conclusion: These studies showed that coadministration of L-thalidomide did not alter the plasma DMXAA AUC in rats, in contrast to previous studies in mice, whereas diclofenac and cyproheptadine significantly reduced the plasma clearance of DMXAA in rats in a similar manner to their effect in mice.”
“In contrast, when combined with diclofenac or cyproheptadine , the plasma AUC of DMXAA was significantly (P<0.05) increased by 48% and 88% and the T1/2 by 36% and 107%, respectively, compared to controls.”
“Purpose: Coadministration of thalidomide, cyproheptadine or diclofenac has been shown to increase the area under the plasma concentration-time curve (AUC) of the novel antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.”
A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide“Conclusion: The augmentation by cyproheptadine of the induction of tumour response to DMXAA reflects a pharmacological interaction, leading to increased plasma and tumour half-lives, and to reduced excretion.”
Help us improve supp.ai, we'd love to hear your feedback: Submit Feedback